Fruquintinib Plus Trifluridine/Tipiracil Shows Promise in Pretreated Metastatic Colorectal Cancer
• A phase 2 trial combining fruquintinib and trifluridine/tipiracil demonstrated clinical activity in heavily pretreated metastatic colorectal cancer (mCRC) patients.
• The combination therapy achieved a median progression-free survival (PFS) of 6.33 months and a median overall survival (OS) of 18.4 months.
• The safety profile of the combination was acceptable, with treatment-related adverse events primarily being hematologic in nature.
• These findings suggest that fruquintinib plus trifluridine/tipiracil could be a potential alternative treatment option for mCRC patients who have progressed on prior therapies.
© Copyright 2025. All Rights Reserved by MedPath